Literature DB >> 8786205

Time-dependent effect of tamoxifen therapy on endometrial pathology in asymptomatic postmenopausal breast cancer patients.

I Cohen1, M M Altaras, J Shapira, R Tepper, D J Rosen, M Cordoba, Y Zalel, A Figer, D Yigael, Y Beyth.   

Abstract

Various endometrial lesions were more frequent among asymptomatic postmenopausal breast cancer patients who were treated with tamoxifen for > 48 consecutive months (30.8%) when compared with similar patients who were treated for 6-24 months or for 25-48 months (20.8% and 12.5%, respectively). However, this difference was not statistically significant. There were also no significant differences in the frequency of the various endometrial lesions between these three groups, although endometrial polyps were more frequently found among those treated for > 48 months. Overall, 20.7% of the 164 tamoxifen-treated patients in the study had an endometrial pathology. It can be concluded that there is a slight tendency among those postmenopausal patients who have been treated for > 48 consecutive months to have a higher frequency of endometrial lesions.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8786205     DOI: 10.1097/00004347-199604000-00010

Source DB:  PubMed          Journal:  Int J Gynecol Pathol        ISSN: 0277-1691            Impact factor:   2.762


  8 in total

1.  Endometrial pathology in postmenopausal tamoxifen treatment: comparison between gynaecologically symptomatic and asymptomatic breast cancer patients.

Authors:  I Cohen; E Perel; D Flex; R Tepper; M M Altaras; M Cordoba; Y Beyth
Journal:  J Clin Pathol       Date:  1999-04       Impact factor: 3.411

Review 2.  Endometrial Cancer and BRCA Mutations: A Systematic Review.

Authors:  Maria Luisa Gasparri; Serena Bellaminutti; Ammad Ahmad Farooqi; Ilaria Cuccu; Violante Di Donato; Andrea Papadia
Journal:  J Clin Med       Date:  2022-05-31       Impact factor: 4.964

3.  Concurrent tamoxifen-related Müllerian adenofibromas in uterus and ovary.

Authors:  Haiyan Shi; Xiaoduan Chen; Bingjian Lv; Xiaofei Zhang
Journal:  Int J Clin Exp Pathol       Date:  2015-11-01

4.  Endometrial polyp surveillance in premenopausal breast cancer patients using tamoxifen.

Authors:  Se Jeong Jeon; Jae Il Lee; Maria Lee; Hee Seung Kim; Jae Weon Kim; Noh Hyun Park; Yong Sang Song
Journal:  Obstet Gynecol Sci       Date:  2017-01-19

5.  A 12-month extension study to evaluate the safety and efficacy of asoprisnil in women with heavy menstrual bleeding and uterine fibroids.

Authors:  M P Diamond; E A Stewart; A R W Williams; B R Carr; E R Myers; R A Feldman; W Elger; C Mattia-Goldberg; B M Schwefel; K Chwalisz
Journal:  Hum Reprod Open       Date:  2019-11-04

6.  Endometrial pathology in breast cancer patients: Effect of different treatments on ultrasonographic, hysteroscopic and histological findings.

Authors:  Maria LE Donne; Angela Alibrandi; Leonarda Ciancimino; Andrea Azzerboni; Benito Chiofalo; Onofrio Triolo
Journal:  Oncol Lett       Date:  2013-01-28       Impact factor: 2.967

7.  The effect of tamoxifen therapy on the endometrium and ovarian cyst formation in patients with breast cancer.

Authors:  Seul Lee; Yun Hwa Kim; Seung Chul Kim; Jong Kil Joo; Dong Suh Seo; Ki Hyung Kim; Kyu Sup Lee
Journal:  Obstet Gynecol Sci       Date:  2018-08-13

Review 8.  Risk Factors Associated with Endometrial Pathology in Premenopausal Breast Cancer Patients Treated with Tamoxifen.

Authors:  Maria Lee; Jinlan Piao; Myung Jae Jeon
Journal:  Yonsei Med J       Date:  2020-04       Impact factor: 2.759

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.